PuraPharm Corp. Ltd. ( (HK:1498) ) has shared an update.
PuraPharm Corporation Limited announced an expected net loss of approximately HK$36 million for the fiscal year ending December 31, 2024, a significant improvement from the HK$106.1 million loss in 2023. This reduction is attributed to decreased impairment losses and fair value losses in their plantation segment, alongside successful cost control measures that reduced administrative and selling expenses. The final results are pending and subject to adjustments, with the official announcement expected by the end of March 2025.
More about PuraPharm Corp. Ltd.
PuraPharm Corporation Limited operates in the health and wellness industry, focusing on the production and distribution of Chinese herbal medicine products. The company is involved in plantation, manufacturing, and sale of its products, primarily targeting markets interested in traditional Chinese medicine.
YTD Price Performance: 1.82%
Average Trading Volume: 87,548
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$221.2M
For an in-depth examination of 1498 stock, go to TipRanks’ Stock Analysis page.